The online version of this article (doi:10.1186/1129-2377-15-65) contains supplementary material, which is available to authorized users.
Haifeng Zhang, Yunqing Ma contributed equally to this work.
The authors declare that they have no competing interest.
Y-JL - Study concept and design. H-FZ - carried out the treatment and studies, drafted the manuscript Y-QM - acquisition of data. C-HH - participated in the sequence alignment, analysis and interpretation. DYC - revise the manuscript. N-CX, C-JW - study supervision. All authors read and approved the final manuscript.
In the majority of cases, trigeminal neuralgia (TN) is a unilateral condition with ultra-short stabbing pain located along one or more branches of the trigeminal nerve. Although prophylactic pharmacological treatment is first choise, considering of insufficient effect or unacceptable side effects, neurosurgical treatment or lesion treatment should be considered. In addition to all these procedures mentioned above, one approach has been based on local intradermal and/or submucosal injections of Botulinum Toxin Type A (BTX-A).
We conducted a randomized, double-blind, placebo-controlled since November 2012, and adopted local multi-point injection in 84 cases of classical TN with different doses of BTX-A. Eighty four patients were randomized into following groups: placebo (n = 28); BTX-A 25U (n = 27); BTX-A 75U (n = 29). Follow-up visits were conducted every week after the injection, and the overall duration of the study for each patient were 8 weeks to observe the pain severity, efficacy and adverse reactions at endpoint.
The visual analogue scale (VAS) scores of 25U and 75U groups reduced significantly compared to placebo as early as week 1, and sustained until week 8 throughout the study. There was no significant difference in VAS between 25U and 75U groups throughout the study. The response rates of 25U group (70.4%) and 75U group (86.2%) were significantly higher than placebo group (32.1%) at week 8, and there was no significant difference between 25U and 75U groups. Evaluation of the Patient Global Impression of Change (PGIC) demonstrated that 66.7% (25U group) and 75.9% (75U group) of the patients reported that their pain symptoms were ‘much improved’ or ‘very much improved’ versus 32.1% of the placebo group, and there was also no significant difference between 25U and 75U groups. All adverse reactions were graded as mild or moderate.
BTX-A injection in TN is safe and efficient. It is a useful treatment for refractory TN. Lower dose (25U) and high dose (75U) were similar in efficacy in short-term.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(suppl 1):9–160.
Turp JC, Gobetti JP: Trigeminal neuralgia--an update. Compend Contin Educ Dent 2000, 21: 279–282. 284, 287–8 passim;quiz 292 PubMed
Bendtsen L, Birk S, Kasch H, Aegidius K, Sorensen PS, Thomsen LL, Poulsen L, Rasmussen MJ, Kruuse C, Jensen R, Danish Headache Society: Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition. J Headache Pain 2012, 13(Suppl 1):S1-S29. CrossRefPubMed
Wu CJ, Shen JH, Chen Y, Lian YJ: Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm. Turk Neurosurg 2011, 21: 625–629. PubMed
Shen JH, Lian YJ, Zheng YK: Effect of botulinum toxin type a on clssic trigeminal neuralgia. Chin J Rehab Med 2011, 26: 483–484.
Piovesan EJ, Leite LS, Teive HG, Kowacs PA, Mulinari RA, Radunz V: Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: a pre-clinical double-blind and placebo-controlled study. Arq Neuropsiquiatr 2011, 69: 56–63. 10.1590/S0004-282X2011000100012 CrossRefPubMed
Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR: Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum boxin with anti-nociceptive potential. J Neurosic 2009, 29: 4981–4992. 10.1523/JNEUROSCI.5490-08.2009 CrossRef
- Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial
- Springer Milan
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II